دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Targeting Immune Checkpoints and Cytokines to Protect From Psoriasis Relapse
Kamran Ghoreschi, MD1
doi : 10.1001/jamadermatol.2021.3491
JAMA Dermatol. 2021;157(11):1269-1271
Risk of Bias and Error From Data Sets Used for Dermatologic Artificial Intelligence
Philipp Tschandl, MD, PhD1
doi : 10.1001/jamadermatol.2021.3128
JAMA Dermatol. 2021;157(11):1271-1273
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa
Sophie Glatt, MD1; Gregor B. E. Jemec, MD2,3; Seth Forman, MD4; Christopher Sayed, MD5; George Schmieder, MD6; Jamie Weisman, MD7; Robert Rolleri, PharmD8; Seth Seegobin, PhD1; Dominique Baeten, MD1; Lucian Ionescu, MD9; Christos C. Zouboulis, MD10; Stevan Shaw, PhD1
doi : 10.1001/jamadermatol.2021.2905
JAMA Dermatol. 2021;157(11):1279-1288
Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a high burden for patients and limited existing therapeutic options.
Sirolimus (Rapamycin) for Slow-Flow Malformations in Children
Annabel Maruani, MD, PhD1,2,3; Elsa Tavernier, PhD1,3; Olivia Boccara, MD4; Juliette Mazereeuw-Hautier, MD, PhD5; Sophie Leducq, MD1,2; Didier Bessis, MD, PhD6; Laurent Guibaud, MD, PhD7; Pierre Vabres, MD, PhD8; Virginie Carmignac, PhD8; Stéphanie Mallet, MD9; Sébastien Barbarot, MD, PhD10; Christine Chiaverini, MD11; Catherine Droitcourt, MD12; Anne-Claire Bursztejn, MD, PhD13; Céline Lengellé, PharmD14; Jean-Baptiste Woillard, PharmD, PhD15; Denis Herbreteau, MD16; Anne Le Touze, MD17; Aline Joly, MD18; Christine Léauté-Labrèze, MD19; Julie Powell, MD, PhD20; Hélène Bourgoin, PharmD21; Valérie Gissot, MD3; Bruno Giraudeau, PhD1,3; Baptiste Morel, MD22
doi : 10.1001/jamadermatol.2021.3459
JAMA Dermatol. 2021;157(11):1289-1298
Sirolimus is increasingly being used to treat various vascular anomalies, although evidence of its efficacy is lacking.
Rates of Opioid Prescriptions Obtained After Mohs Surgery
Surya A. Veerabagu, BA1; Brian Cheng, BS2; Sonia Wang, BS3; Jeremy R. Etzkorn, MD, MS4; Austin S. Kilaru, MD, MSHP5; Megan H. Noe, MD, MPH, MSCE6; Christopher J. Miller, MD4; Joseph F. Sobanko, MD4; Thuzar M. Shin, MD, PhD4; H. William Higgins II, MD, MBE4; Stacy L. McMurray, MD4; Aimee E. Krausz, MD4; Joanna L. Walker, MD4; Cerrene N. Giordano, MD4
doi : 10.1001/jamadermatol.2021.3468
JAMA Dermatol. 2021;157(11):1299-1305
To curtail the opioid epidemic, physicians have been advised to limit opioid prescriptions.
Effect of Costimulatory Blockade With Abatacept After Ustekinumab Withdrawal in Patients With Moderate to Severe Plaque Psoriasis
Kristina M. Harris, PhD1; Dawn E. Smilek, MD, PhD2; Margie Byron, MStat3; Noha Lim, PhD1; William T. Barry, PhD3; James McNamara, MD4; Sandra Garcet, PhD5; Robert J. Konrad, MD6; Martin Stengelin, PhD, MBA7; Pradeepthi Bathala, MS7; Neil J. Korman, MD, PhD8; Steven R. Feldman, MD, PhD9; Erin E. Boh, MD, PhD10; Kirk Barber, MD11; Anne E. Laumann, MBChB12; Yolanda Rosi Helfrich, MD13; Gerald G. Krueger, MD14; Howard Sofen, MD15; Robert Bissonnette, MD16; James G. Krueger, MD, PhD5
doi : 10.1001/jamadermatol.2021.3492
JAMA Dermatol. 2021;157(11):1306-1315
Psoriasis relapse may involve compensatory T-cell activation pathways in the presence of CD28-CD80/CD86 blockade with abatacept.
Evaluation of Pharmacologic Treatments for H1 Antihistamine–Refractory Chronic Spontaneous Urticaria
Surapon Nochaiwong, PharmD1,2; Mati Chuamanochan, MD2,3; Chidchanok Ruengorn, PhD1,2; Ratanaporn Awiphan, PhD1,2; Napatra Tovanabutra, MD3; Siri Chiewchanvit, MD2,3
doi : 10.1001/jamadermatol.2021.3237
JAMA Dermatol. 2021;157(11):1316-1327
The comparative benefits and harms of all available treatments for H1 antihistamine–refractory chronic spontaneous urticaria (CSU) have not been established.
Mapping of Segmental and Partial Segmental Infantile Hemangiomas of the Face and Scalp
Alyson A. Endicott, MD1; Sarah L. Chamlin, MD2,3; Beth A. Drolet, MD4; Anthony J. Mancini, MD2,3; Dawn H. Siegel, MD5; Sterling Vitcov, BS1; Erin F. Mathes, MD1; Ilona J. Frieden, MD1; Anita N. Haggstrom, MD6
doi : 10.1001/jamadermatol.2021.3479
JAMA Dermatol. 2021;157(11):1328-1334
Recognizing segmental infantile hemangioma (IH) patterns is important for risk stratification and provides clues to pathogenesis. Previously, segmental hemangiomas were mapped to 4 facial regions, 3 corresponding to known facial metameres.
Clinicopathologic Characteristics and Response to Treatment of Persistent Chemotherapy-Induced Alopecia in Breast Cancer Survivors
Bevin Bhoyrul, MBBS1; Leila Asfour, MBChB2; Gerhard Lutz, PhD3,4; Lorne Mitchell, MBChB5; Rebekka Jerjen, MChD1; Rodney D. Sinclair, MD1,6; Susan Holmes, MD5; Iskander H. Chaudhry, MBChB7; Matthew J. Harries, PhD2,8
doi : 10.1001/jamadermatol.2021.3676
JAMA Dermatol. 2021;157(11):1335-1342
Alopecia induced by classic chemotherapy affects up to 65% of patients and is usually reversible. However, there are increasing reports of persistent chemotherapy-induced alopecia (pCIA), especially for patients treated with taxane-containing chemotherapy regimens.
Assessment of Clinical and Laboratory Use of the Cutaneous Direct Immunofluorescence Assay
Julie D. R. Reimann, MD, PhD1,2,3,4,5; Sean P. Moynihan, MS1; Thomas D. Horn, MD, MBA1,2,3,4,5
doi : 10.1001/jamadermatol.2021.3892
JAMA Dermatol. 2021;157(11):1343-1348
Dermatologists submit direct immunofluorescence (DIF) biopsies on a daily basis, using an assay detecting immunoreactant deposition with a panel that has traditionally comprised immunoglobulin (Ig) G, IgA, IgM, C3, and fibrin, with or without albumin antibodies.
UBA1 Variations in Neutrophilic Dermatosis Skin Lesions of Patients With VEXAS Syndrome
Eve Zakine, MD1,2; Bérénice Schell, MD2,3; Maxime Battistella, MD, PhD2,4; Marie-Dominique Vignon-Pennamen, MD4; François Chasset, MD, PhD5; Thibault Mahévas, MD1; Florence Cordoliani, MD1; Lionel Adès, MD, PhD6; Marie Sébert, MD, PhD6; Jérémie Delaleu, MD1; Marie Jachiet, MD1; Clémence Lepelletier, MD1; Pierre Lemaire, MD3; Clémentine Chauvel, MD3; Bedis Dhouaieb, MD3; Rathana Kim, MD2,3; Charles Cassius, MD1,2; Sophie Georgin-Lavialle, MD, PhD7; Arsène Mekinian, MD, PhD8; Martine Bagot, MD, PhD1,2; Thorsten Braun, MD, PhD9; Laurie Rousset, MD10; Edouard Begon, MD11; Adèle de Masson, MD, PhD1,2; Pierre Fenaux, MD, PhD6; Emmanuelle Clappier, MD, PhD2,3; Jean-David Bouaziz, MD, PhD1,2
doi : 10.1001/jamadermatol.2021.3344
JAMA Dermatol. 2021;157(11):1349-1354
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) is a recently described severe adult-onset autoinflammatory disease that is associated with myeloid lineage-restricted ubiquitin-activating enzyme 1 (UBA1) somatic variations that primarily affect the skin (Sweet syndrome), cartilage, and bone marrow. Skin symptoms have been poorly described.
Inflation-Adjusted Trends in Medicare Reimbursement for Common Dermatologic Procedures, 2007-2021
Rishabh S. Mazmudar, BS1,2; Anjani Sheth, BA3; Raghav Tripathi, MD, MPH1,2; Jeremy S. Bordeaux, MD, MPH1,2; Jeffrey F. Scott, MD4
doi : 10.1001/jamadermatol.2021.3453
JAMA Dermatol. 2021;157(11):1355-1358
Medicare enrollment, dermatologist utilization of Medicare, and dermatologic procedural volume have all increased over time. Despite this, there are limited studies evaluating changes in Medicare reimbursement within dermatology.
Lack of Transparency and Potential Bias in Artificial Intelligence Data Sets and Algorithms
Roxana Daneshjou, MD, PhD1,2; Mary P. Smith, MD3; Mary D. Sun, MSCR4; Veronica Rotemberg, MD, PhD5; James Zou, PhD6,7,8
doi : 10.1001/jamadermatol.2021.3129
JAMA Dermatol. 2021;157(11):1362-1369
Clinical artificial intelligence (AI) algorithms have the potential to improve clinical care, but fair, generalizable algorithms depend on the clinical data on which they are trained and tested.
Cutaneous Lupus Erythematosus of the Vulvar Skin
Samar Sheriff, MD, MBA1; Jeffrey P. Callen, MD1; Courtney R. Schadt, MD1
doi : 10.1001/jamadermatol.2021.3293
JAMA Dermatol. 2021;157(11):1370
Minute Acral Melanoma
Reiko Tsutsumi, MD, PhD1; Yuichi Yoshida, MD, PhD1; Osamu Yamamoto, MD, PhD1
doi : 10.1001/jamadermatol.2021.3298
JAMA Dermatol. 2021;157(11):1371
Widespread Erythematous Plaques With Prominent Telangiectases
Ayan Kusari, MD1; Philip E. LeBoit, MD1,2,3; Anna Haemel, MD1
doi : 10.1001/jamadermatol.2021.4068
JAMA Dermatol. 2021;157(11):1376-1377
Prevalence and Characterization of Itch in Pachyonychia Congenita
Lloyd Steele, MBChB1; Janice Schwartz, BA2; C. David Hansen, MD2,3; Edel A. O’Toole, PhD1
doi : 10.1001/jamadermatol.2021.3335
JAMA Dermatol. 2021;157(11):1378-1380
Improvement of Chronic Kidney Disease–Associated Pruritus After Treatment With Intravenous Naloxone
Manuel P. Pereira, MD, PhD1; Claudia Zeidler, MD1; Sonja Ständer, MD1
doi : 10.1001/jamadermatol.2021.3829
JAMA Dermatol. 2021;157(11):1380-1381
Evaluation and Treatment of Febrile Ulceronecrotic Mucha-Habermann Disease With Ruxolitinib and Tocilizumab as Guided by Cytokine Profile
Richard Wu, MD1; Ashley DiLorenzo, MD2; Michael Lotke, MD3; Kaiane Habeshian, MD4,5; Joel Brooks, DO5,6; Michael D. Keller, MD5,6; A. Yasmine Kirkorian, MD4,5
doi : 10.1001/jamadermatol.2021.4047
JAMA Dermatol. 2021;157(11):1381-1383
What Are We Waiting for?—Start Screening High-risk Individuals for Anal Cancer Now
Joseph P. Terlizzi, MD1; Jonathan Baker, PA-C1; Stephen E. Goldstone, MD1
doi : 10.1001/jamadermatol.2021.3832
JAMA Dermatol. 2021;157(11):1383-1384
What Are We Waiting for?—Start Screening High-risk Individuals for Anal Cancer Now—Reply
Justin D. Arnold, MD, MMSc1; Anne K. Monroe, MD, MSPH2; Stephen E. Abbott, MD3
doi : 10.1001/jamadermatol.2021.3415
JAMA Dermatol. 2021;157(11):1384
Errors in Abstract, Key Points, Figures, and a Table
doi : 10.1001/jamadermatol.2021.4442
JAMA Dermatol. 2021;157(11):1384
